The NanOX system is the first complete solution on the market dedicated to warm kidney perfusion before transplantation. It allows for keeping the kidney alive outside the body, supporting metabolic processes. It enables the use of organs with higher risk, particularly from donors after circulatory arrest (DCD). It doubles the potential transplant market, reducing healthcare and social costs for long-term dialysis patients. It consists of the NanOX 4 Kidney perfusion fluid, based on our respiratory gas transfer technology, the NanOX Recovery Box perfusion device, and a single-use perfusion kit. NanOX 4 Kidney Perfusion Device - Defined fluid temperature range from 4°C to 37°C - Circulation condition simulation - Continuous data registration - Emergency power supply - Development platform for additional organs
development of dialysis support filtration – expansion of specialization in the field of kidney disease treatment – nephrology – currently being developed by DOTO Medical As part of this activity, NanoGroup plans to continue the Pure Biologics/Doto Medical project in the future, which aims to develop an innovative medical device based on the developed aptamer technology. According to the adopted assumptions, the medical device under development (selective biomolecular filter) should significantly improve the effectiveness of removing toxins from the body during hemodialysis performed on patients suffering from, for example, chronic kidney disease (CKD). The project has been divided into subprojects (A) and (B), each of which will develop an adsorber (filter) targeting different molecular targets. The effect of toxin capture by the adsorbent (A) will be to preserve residual kidney function, while the use of the adsorbent developed in project (B) will reduce the risk of cardiovascular disease and mortality in patients with CKD.
CATEGORY
This allows for improving their efficiency and safety. FLEXIBILITY Enables quick initiation of new projects, leading to the creation of derivative patents based on the core technology. LIMITED RISK Uses known and well-researched active substances with established therapeutic profiles and side effects, reducing developmental risks. REPEATABILITY OF THE PROJECT The polysaccharide nanoparticle technology accelerates project execution by leveraging the effects of previous studies. STRONG SCIENTIFIC FOUNDATION Research conducted in international centers forms the foundation for derivative projects.
CATEGORY
NanOX 4 Kidney Perfusion Fluid Successful Autotransplantation After a 30-minute ischemia simulation, a pig kidney was removed and subjected to a 12-hour ex vivo perfusion at 25°C using the NanOX fluid and device, followed by a successful autotransplantation back into the donor. A 14-day observation period ended successfully. 147 Hours of Ex-Vivo Storage We achieved a breakthrough in organ storage research, maintaining an organ in a viable state outside the body for 147 hours – longer than any existing solution on the market.
CATEGORY
We possess proprietary, widely patented technology for the production and integration of polysaccharide nanoparticles. Our polysaccharide nanoparticles utilize two targeting mechanisms: 1. Drug Release Based on Intracellular pH Level – Nanoparticles enter the cell through endosomes. As a result of the low pH in the endosome, the bond breaks and the active substance is released. 2. EPR Effect (Enhanced Permeability and Retention) – The rapid growth of tumor cells requires increased blood supply, resulting in greater permeability of blood vessels. Nanoparticles sized 100-200nm have a higher chance of reaching cancer cells.
CATEGORY
